|
DSP Healthcare Fund An open ended equity scheme investing in healthcare and pharmaceutical sector |
|
|
Aditya Khemka
Total work experience of 11 years.
Managing this Scheme since November
2018.
Vinit Sambre
Total work experience of 19 years.
Managing this Scheme since November
2018.
Jay Kothari (Dedicated Fund Manager
for overseas investments)
Total work experience of 14 years.
Managing this Scheme since November
2018.
Nov 30, 2018
S&P BSE HEALTHCARE (TRI)
| Regular Plan | |
| Growth: | ₹ 10.531 |
| Direct Plan | |
| Growth: | ₹ 10.699 |
₹ 235 Cr
₹ 221 Cr
0.09
| Regular Plan : | 2.45% |
| Direct Plan : | 0.95% |
Holding period <12 months: 1%
Holding period >=12 months: Nil
| Name of Instrument | % to Net Assets |
| EQUITY & EQUITY RELATED | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 78.38% |
| ✔ Sun Pharmaceutical Industries Limited | 12.53% |
| ✔ IPCA Laboratories Limited | 10.35% |
| ✔ Dr. Reddy's Laboratories Limited | 8.46% |
| ✔ Divi's Laboratories Limited | 6.69% |
| ✔ Indoco Remedies Limited | 4.52% |
| ✔ Jubilant Life Sciences Limited | 4.15% |
| ✔ JB Chemicals & Pharmaceuticals Limited | 4.11% |
| Unichem Laboratories Limited | 3.53% |
| Procter & Gamble Health Limited | 3.42% |
| Alembic Pharmaceuticals Limited | 3.35% |
| Abbott India Limited | 3.16% |
| Syngene International Limited | 3.01% |
| Ajanta Pharma Limited | 2.95% |
| Alkem Laboratories Limited | 2.94% |
| Aarti Drugs Limited | 2.72% |
| Torrent Pharmaceuticals Limited | 2.46% |
| Healthcare Services | 11.98% |
| ✔ Apollo Hospitals Enterprise Limited | 5.83% |
| ✔ Max India Limited | 4.08% |
| Dr. Lal Path Labs Ltd. | 2.06% |
| Finance | 1.57% |
| ICICI Lombard General Insurance Company Limited | 1.57% |
| Total | 91.89% |
| Foreign Securities and/or overseas ETF(s) | |
| Listed / awaiting listing on the stock exchanges | |
| healthcare Services | 3.56% |
| ✔ Abiomed Inc | 3.56% |
| Pharmaceuticals | 2.81% |
| Abbott Laboratories | 2.81% |
| Total | 6.37% |
| MONEY MARKET INSTRUMENTS | |
| TREPS / Reverse Repo Investments / Corporate Debt Repo | 1.48% |
| Total | 1.48% |
| Cash & Cash Equivalent | |
| Net Receivables/Payables | 0.26% |
| Total | 0.26% |
| GRAND TOTAL | 100.00% |
✔ Top 10 Holdings
| Positions Increased |
| Stock |
| Pharmaceuticals |
| Syngene International Limited |
| Jubilant Life Sciences Limited |
| IPCA Laboratories Limited |
| Indoco Remedies Limited |
| JB Chemicals & Pharmaceuticals Limited |
| Aarti Drugs Limited |
| Positions Decreased |
| Stock |
| Pharmaceuticals |
| Unichem Laboratories Limited |
Rebalances below 0.05 % are not considered.
The primary investment objective of the
scheme is to seek to generate consistent
returns by predominantly investing in
equity and equity related securities of
pharmaceutical and healthcare companies.
However, there can be no assurance that
the investment objective of the scheme will
be realized.
This open ended equity Scheme is suitable for investors who are seeking*
• Long term capital growth
• Investment in equity and equity related Securities of healthcare and pharmaceutical companies
* Investors should consult their financial advisors if in doubt whether the product is suitable for them.